Climb Bio Budoprutug Phase 1b, First Anti-CD19 Antibody in ITP

Summary Climb Bio presented the first clinical data for budoprutug, an anti-CD19 monoclonal antibody, in primary immune thrombocytopenia (ITP). Early Phase 1b results demonstrated robust B-cell depletion, encouraging safety, and meaningful platelet responses in heavily pretreated patients, introducing a new mechanistic approach into an increasingly…